ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CGON vs SRRK // OPERATING MARGIN

CG Oncology Inc. (NASDAQ) VS. Scholar Rock Holding Corporation (NASDAQ) • 15-METRIC TALLY: CGON 7 — SRRK 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGON VS. SRRK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CGON SRRK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -20.80% -35.00% +14.20 CGON /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -2.35% -5.59% +3.24 CGON /fcf-yield <GO>
Operating Margin ACTIVE -12.10% — — TIE /operating-margins <GO>
Net Profit Margin -10.20% — — TIE /net-margins <GO>
Revenue Growth (YoY) 8.80% 7.70% +1.10 CGON /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 13.67 +12.33 CGON /balance-sheet <GO>
Piotroski F-Score Quality 5/9 5/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.5 44.5 -3.00 SRRK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.07 1.02 +0.05 CGON /macro-sensitivity <GO>
Forward P/E Multiple 20.0x 32.0x -12.00 CGON /forward-pe <GO>
Enterprise Scale & Market Cap $5.49B $5.23B $266.4M CGON /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CGON REV SRRK REV CGON GROSS % SRRK GROSS % CGON FCF SRRK FCF
FY 2025 $534.2M $1.08B — — -$132.5M -$300.6M
FY 2024 $321.1M $705.8M — — -$78.9M -$201.0M
FY 2023 $155.3M $479.6M — — -$45.7M -$145.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGON // BETA 1.07
SRRK // BETA 1.02